alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 851–875 of 900 studies · free to read (page 35 of 36) · 27,380 in the whole library · How the 0–100 score works

Showing 900 studies tagged precursor — clear

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

α‐Synuclein seed amplification assay in Lewy body dementia versus Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2025-10-01

The accuracy of α-synuclein-SAA for DLB was 87% (95% confidence interval [CI]: 77% to 98%) in CSF, 85% (95% CI: 75% to 98%) in skin, 58% (95% CI: 47% to 69%) in olfactory mucosa, and 59% (95% CI: 51% to 66%) in urine. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association of residential neighborhood disadvantage with amyloid PET positivity among cognitively impaired individuals

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Carolina Digital Repository (University of North Carolina at Chapel Hill) 2026-05-29

Among 15,346 White, 829 Latino, 637 Black/African American, and 321 Asian individuals, 51% were female, mean age was 75.7 years, 535 (3.8%) resided in ADI 91 to 100 decile, and 61.6% were amyloid PET positive. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Combating Genetic Heterogeneity for Polygenic Prediction of Susceptibility to Brain β-Amyloid Deposition

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Neurology Genetics 2025-07-21

The APOE (apolipoprotein E) ε4 allele is the strongest known genetic risk factor for sporadic Alzheimer disease (AD) and for brain amyloidosis, an early marker of disease pathophysiology. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effects of sexual differentiation and APOE genotype on the development of Alzheimer-related pathology in female EFAD mice

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Biology of Sex Differences 2026-08-12

These findings suggest that sexual differentiation in early life has modest effects on adult development of AD in females, a relationship that appeared stronger in the context of APOE4 . 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Genetic Colocalization of Expression Quantitative Trait Loci (eQTL) Mapping and GWAS in a multiethnic brain bank: An Insight into ancestry‐specific Regulatory Architecture in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Alzheimer s & Dementia 2025-12-01

In the colocalization of cis-eQTL and GWAS signals for Hispanics, we observed a high posterior probability (posterior prob = 0.9947) for the upstream gene variant rs755980338 on chromosome 11, which locally regulates EHD1 gene (GWAS p-value = 0.009, cis-eQTL p-value = 0.0041). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Identifying potential drug targets for cerebral amyloid angiopathy: A Mendelian randomization study based on the druggable genes

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Medicine 2025-10-31

Cerebral amyloid angiopathy (CAA), which is prevalent among older adults, constitutes a major cause of brain hemorrhage, dementia, and cognitive decline. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alismatis Rhizoma prevents AβO-induced neuronal cell death and synaptic loss in Alzheimer’s disease models

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Frontiers in Pharmacology 2026-09-04

In AβO-injected mice, AR, particularly at 200 mg/kg, attenuated memory deficits, reduced hippocampal neuronal degeneration, preserved synaptic protein immunoreactivity and increased markers of hippocampal cell proliferation and immature neurons. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mapping the impact of age and APOE risk factors for late onset Alzheimer's disease on long range brain connections through multiscale bundle analysis

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Brain structure & function 2025-03-20

Alzheimer's disease currently has no cure and is usually detected too late for interventions to be effective. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

T cell drives microglia specific metabolic plasticity and neurodegeneration in Alzheimer disease 4098

✓ Peer-reviewed alzhub usefulness score 31 out of 100. The Journal of Immunology 2025-11-01

Of note, using large-scale transcriptome and chromatin profiling, we show that T cell shape microglia-specific metabolic plasticity in both genetic and epigenetic resolution. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cryo‐EM structures of amyloid β filaments from cotton wool plaques in Alzheimer disease caused by the PSEN1 V261I and A431E mutations

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Alzheimer s & Dementia 2025-12-01

CWPs consist predominantly of two novel arrangements of type I Aβ filaments, and we have designated them as type Ic and type Id Aβ filaments. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cerebral Amyloid Angiopathy With Progressive Cortical Superficial Siderosis and Convexity Subarachnoid Hemorrhage in an Apolipoprotein E (APOE) ε2/ε2 Homozygous Patient: A Case Report and Literature Review

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Cureus 2025-06-29

It is associated with intracerebral hemorrhage (ICH), cognitive decline, and gait disturbance. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Genome‐Wide Analysis of Memory, Language, and Executive Function Reveals Domain‐Specific Genetic Architecture in Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 30 out of 100. Alzheimer s & Dementia 2025-12-01

We evaluated known AD-associated loci (Bellenguez et al. 2022) and 27 loci reached nominal significance (p < 0.05) in at least one cognitive domain. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Single-cell atlas reveals pathological amplification of aging programs and proteostasis collapse in microglia of Alzheimer′s disease mice

✓ Peer-reviewed alzhub usefulness score 30 out of 100. DOAJ (DOAJ: Directory of Open Access Journals) 2026-06-01

The pathological activation of AD microglia significantly amplifies endogenous aging characteristics. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Role of GFAP as a Marker of Astrocyte Activation in the Pathogenesis of Alzheimer's Dementia: A Literature Review

✓ Peer-reviewed alzhub usefulness score 28 out of 100. Health & Medical Sciences 2025-12-09

This study aims to comprehensively review the role of glial fibrillary acidic protein (GFAP) as a marker of astrocyte activation in Alzheimer's disease (AD). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer-typical temporo-parietal atrophy and hypoperfusion are associated with a more significant cholinergic impairment in amnestic neurodegenerative syndromes

✓ Peer-reviewed alzhub usefulness score 27 out of 100. JuSER Publikationsportal 2025-01-01

However, postmortem investigations indicate that the AD-typical progressive amnestic syndrome may also result from predominantly limbic non-AD neuropathology such as TDP-43 proteinopathy and argyrophilic grain disease. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

In silico structure-based multi-targeted molecular docking analysis of ginkgo biloba phytocompounds against Alzheimer’s disease associated proteins

✓ Peer-reviewed alzhub usefulness score 27 out of 100. In Silico Research in Biomedicine 2026-01-01

Alzheimer disease (AD) is a multi-factorial neurodegenerative disease that is characterized by accumulation of amyloid-beta (Aβ), protein aggregation and progressive neuronal dysfunction. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Development of Biotin and Horseradish Peroxidase Labelling against Monoclonal Antibody Amyloid-β42 and Its Application on Enzyme-Linked Immunosorbent Assay

✓ Peer-reviewed alzhub usefulness score 25 out of 100. Jurnal Penelitian Pendidikan IPA 2025-10-25

Alzheimer disease is one of the causes of dementia that could make the patient lose their memories until they unable to do normal activities. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons

⚠ Retracted — do not rely on it alzhub usefulness score 16 out of 100. Cell 2011-08-01

Directed conversion of mature human cells, as from fibroblasts to neurons, is of potential clinical utility for neurological disease modeling as well as cell therapeutics. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed